Bombay High Court Rejects Plea To Restrain Serum Institute Of India From Using ‘COVISHIELD’ Trademark

Posted On - 20 April, 2021 • White & Brief

The Bombay High Court on Tuesday refused to grant interim relief to pharmaceutical company Cutis Biotech and restrain Serum Institute of India (SII) from using the trademark ‘Covishield,’ for its coronavirus vaccine. A division bench of Justices Nitin Jamdar and C. V. Bhadang said that the Nanded civil court’s order, refusing Cutis an injunction against Serum Institute was not…

Related Posts

low angle photo of city high rise buildings during daytimeA person holding a credit card in their handlow angle photo of curtain wall building during daytimeBoardroom Vanguard: How Enforcement Synergy Is Recasting Corporate Risk in India